Rising Drug Development Complexity and Demand for Biologics Drive Market Growth

AUSTIN, TX, UNITED STATES, February 24, 2025 /EINPresswire.com/ -- According to SNS Insider, the Pharmacokinetics Services Market, valued at USD 1.19 billion in 2023, is projected to reach USD 2.32 billion by 2032, expanding at a CAGR of 7.70% from 2024 to 2032. Increasing demand for precise pharmacokinetic (PK) studies in drug development, rising chronic disease prevalence, and advancements in AI-driven PK modeling are key factors fueling market growth.

Market analysis
The major factors driving the pharmacokinetics services market include increasing focus on personalized medicine and rising need for rapid drug development processes. Outsourcing of PK studies has become a trend due to the growing prevalence of chronic diseases and the increasing complexity of drug formulations. This trend is even reinforced by the FDA and the European Medicines Agency (EMA) which are requiring detailed PK data for drug approval. PK studies, by way of example, have benefitted from improved analytical technologies, including HPLC and mass spectrometry, that contribute to precise and efficient characterization of a new compound’s potato, if you will, over time. Besides, AI and ML techniques are being increasingly utilized in pharmacokinetic modeling, leading to a paradigm shift in the way drug development is performed, making it economical and sustainable. Furthermore, growing government initiatives and funding for drug research such as U.S. National Institutes of Health (NIH) grants and European Union’s Horizon Europe program are also propelling market growth.

Get a Free Sample Report@ https://www.snsinsider.com/sample-request/5723

Key Players in Pharmacokinetics Services Market
• Charles River Laboratories (Preclinical PK Studies, Drug Metabolism & Pharmacokinetics Services)
• Labcorp Drug Development (Pharmacokinetics Testing, Clinical PK Studies)
• Covance (Bioanalytical Services, Early Clinical Services)
• WuXi AppTec (Pharmacokinetic Studies, Bioanalytical Testing Services)
• PRA Health Sciences (Pharmacokinetic Analysis, Drug Metabolism Studies)
• Syneos Health (Clinical Pharmacokinetics, PK/PD Modeling)
• Quotient Sciences (Pharmacokinetic Studies, Clinical Trials)
• Medpace (Pharmacokinetics Services, Clinical Pharmacology)
• Pharmaron (PK/PD Modeling & Simulation, Preclinical Pharmacokinetics)
• KCR (Clinical PK Analysis, Preclinical Drug Testing)
• Celerion (Clinical Pharmacokinetics Services, Bioanalytical Testing)
• ICON plc (PK Study Design, Clinical Pharmacokinetic Services)
• Eurofins Scientific (Pharmacokinetics Studies, Analytical Services)
• Toxikon (Pharmacokinetic Testing, Drug Development Services)
• Roche (Pharmacokinetics Modeling, Drug Metabolism Testing)
• Boehringer Ingelheim (Pharmacokinetics Services, Preclinical Research)
• Pharmalex (Clinical Pharmacokinetic Services, Preclinical Pharmacokinetic Studies)
• Accelsiors (Pharmacokinetics Services, PK/PD Modeling)
• XenoTech, LLC (In-vitro Pharmacokinetic Services, Metabolism & Transport Studies)
• Bioreliance (Pharmacokinetics Testing, Drug Development Services)

Market Segmentation

By Drug Type
In 2023, small molecules accounted for 75.23% of total revenue with a dominant share of the pharmacokinetics services market. Small molecules such as classic antibiotics and antihypertensives are of significant therapeutic interest for decades because of their well-characterized pharmacokinetics. Because these molecules are less difficult to synthesize and analyze, many PK studies can choose to use this type. But their high molecular weight and complex composition are challenges that require advanced technologies and expertise in PK analysis.

By Application
In 2023, the SMEs segment dominated the pharmacokinetics services market, held a 60.86% share of the market. SMEs, particularly in the pharmaceutical and biotechnology sectors, are increasingly outsourcing PK studies to reduce operational costs and accelerate drug development timelines. These companies often lack the in-house capabilities and infrastructure required for comprehensive PK analysis, making them reliant on specialized service providers. Big Pharma companies join the market with large contributions as they use pharmacokinetics services in late phase clinical trials and regulatory submission. Market growth is additionally propelled by the rise in strategic partnerships between pharmaceutical companies and vitamin contract research organizations (CROs).

By End Use
In 2023, the pharmacokinetics services market was dominated by the academic & government research institutes segment, which held 44.56% of the market. These institutions are key players in drug discovery and early-stage preclinical research, frequently partnering with pharmaceutical companies and the CRO to carry out PK studies. Government-sponsored research programs, including the NIH’s Clinical and Translational Science Awards (CTSA) program, are driving up demand for pharmacokinetics services. Pharmaceutical & biotechnology companies is anticipated to witness the fastest growth during the forecasted period as they are heavily outsourcing the PK studies that commonly help them in drug development and regulatory compliance. Moreover, the growing utilization of pharmacokinetics services in contractual research organizations (CROs) is fueling the market growth.

Speak with Our Expert Analyst Today to Gain Deeper Insights @ https://www.snsinsider.com/request-analyst/5723

Regional Analysis
In 2023, North America led the pharmacokinetics services market, contributing to 38.35% of total revenue. It is a reflection of the region’s established pharmaceutical and biotechnology industries, high R&D spend, and rigorous regulatory approval standards for drugs. The U.S. is a key player as FDA requires detailed PK data for all new drug applications (NDAs). According to recent statistics from the NIH, the U.S. government invested USD 45 billion in medical research in 2023, which will act as a positive factor for market growth.

Rapid enhancement in healthcare infrastructure and rise in investments in drug development are anticipated to drive the pharmacokinetics services market in the Asia Pacific region, which is estimated to follow the highest growth in the market. Emerging key players include China, India, and Japan, whose governments are rolling out initiatives to improve pharmaceutical research. India’s Department of Biotechnology (DBT) allocated INR 2,200 crore (USD 265 million) for various biotechnology research in 2023.

Recent Developments
• In 2023, Charles River Laboratories expanded its pharmacokinetics services portfolio by introducing advanced bioanalytical platforms for small molecules and biologics.
• In January 2024, Labcorp received FDA approval for its innovative PK modeling software, which integrates AI to predict drug behavior in the human body.

Buy Full Research Report on Pharmacokinetics Services Market 2024-2032 @ https://www.snsinsider.com/checkout/5723

About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Jagney Dave
SNS Insider Pvt. Ltd
+1 315 636 4242
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.